Pharmacotherapy and pregnancy: Highlights from the second international conference for individualized pharmacotherapy in pregnancy

Clinical and Translational Science

Volumn 2, Issue 6, 2009, Pages 439-443

  Haas, David M ^a   Hebert, Mary F ^b   Soldin, Offie P ^c   Flockhart, David A ^a   Madadi, Parvaz ^d   Nocon, James J ^a   Chambers, Christina D ^e   Hankins, Gary D ^f   Clark, Shannon ^f   Wisner, Katherine L ^g   Li, Lang ^a   Renbarger, Jamie L ^a   Learman, Lee A ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Pharmacogenomic; Pharmacology; Pregnancy

Indexed keywords

BUPRENORPHINE; CYTOCHROME P450 2D6; LEVOTHYROXINE; METHADONE; SEROTONIN UPTAKE INHIBITOR; THYROXINE; THYROXINE BINDING GLOBULIN;

ADDICTION; ARTICLE; BLOOD VOLUME; DRUG UTILIZATION; ENZYME ACTIVITY; EVIDENCE BASED PRACTICE; FIRST TRIMESTER PREGNANCY; GENOME ANALYSIS; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HUMAN; HYPOTHYROIDISM; LACTATION; MAJOR DEPRESSION; OPIATE ADDICTION; PHARMACOGENETICS; POSTMARKETING SURVEILLANCE; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL FOR DATE INFANT; SUBSTANCE ABUSE; TERATOLOGY; THYROID DISEASE;

BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP2D6; DECISION MAKING; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LACTATION; MODELS, BIOLOGICAL; PHARMACOGENETICS; PHARMACOKINETICS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; SEROTONIN UPTAKE INHIBITORS; TERATOLOGY; THYROID DISEASES;

EID: 77953428242     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2009.00166.x     Document Type: Article

References (44)

1. Updated Interim Recommendations for Obstetric Health Care Providers Related to Use of Antiviral Medications in the Treatment and Prevention of Infl uenza for the 2009-2010 Season. http://www.cdc.gov/H1N1flu/pregnancy/antiviral_messages.htm, Centers for Disease Control and Prevention, Available at, Updated September 17, 2009. Accessed September 24, 2009
2. Haas DM, Renbarger JL, Denne S, Ahmed MS, Easterling TR, Feibus K, Meslin EM, Koren G, Zajicek A, Snodgrass WR, Flockhart DA. Pharmacotherapy and Pregnancy: highlights from the First International Conference for Individualized Pharmacotherapy in Pregnancy. Clin Transl Sci. 2009, 2:11-14.
3. Yeomans ER, Gilstrap LC. Physiologic changes in pregnancy and their impact on critical care. Crit Care Med. 2005, 33:S256-S258.
4. Hill CC, Pickinpaugh J. Physiologic changes in pregnancy. Surg Clin North Am. 2008, 88:391-401. vii
5. Metcalfe J, Romney SL, Ramsey LH, Reid DE, Burwell CS. Estimation of uterine blood flow in normal human pregnancy at term. J Clin Invest. 1955, 34:1632-1638.
6. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol. 2001, 25:120-123.
7. Robson SC, Mutch E, Boys RJ, Woodhouse KW. Apparent liver blood flow during pregnancy: a serial study using indocyanine green clearance. Br J Obstet Gynaecol. 1990, 97:720-724.
8. Lee W. Cardiorespiratory alterations during normal pregnancy. Crit Care Clin. 1991, 7:763-775.
9. Mattison DR, Malek A, Cistola C, Yaffe SJ, Aranda JV. Physiologic adaptations to pregnancy: impact on pharmacokinetics. Pediatric Pharmacology: Therapeutic Principles in Practice 1992, In, eds, Philadelphia, WB Saunders
10. Parry E, Shields R, Turnbull AC. Transit time in the small intestine in pregnancy. J Obstet Gynaecol Br Commonw. 1970, 77:900-901.
11. Gryboski WA, Spiro HM. The effect of pregnancy on gastric secretion. N Engl J Med. 1956, 255:1131-1134.
12. Davison JM. The effect of pregnancy on kidney function in renal allograft recipients. Kidney Int. 1985, 27:74-79.
13. Lindheimer MD, Davison JM, Katz AI. The kidney and hypertension in pregnancy: twenty exciting years. Semin Nephrol. 2001, 21:173-189.
14. Davison JM, Dunlop W, Ezimokhai M. 24-hour creatinine clearance during the third trimester of normal pregnancy. Br J Obstet Gynaecol. 1980, 87:106-109.
15. Davison JM, Noble MC. Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the fi rst trimester of pregnancy. Br J Obstet Gynaecol. 1981, 88:10-17.
16. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T, Bennett R, Vicini P, Hebert MF. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther. 2007, 81:547-556.
17. Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, Rutherford T, Thummel KE, Fishbein DP, Unadkat JD. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008, 84:248-253.
18. Hebert MF, Carr DB, Anderson GD, Blough D, Green GE, Brateng DA, Kantor E, Benedetti TJ, Easterling TR. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and post-partum. J Clin Pharmacol. 2005, 45:25-33.
19. Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005, 192:633-639.
20. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, Looareesuwan S, White NJ, Nosten F. Pregnancy and use of oral contraceptives reduces the bio-transformation of proguanil to cycloguanil. Eur J Clin Pharmacol. 2003, 59:553-557.
21. Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GD, Caritis SN, Miodovnik M, Mattison DR, Unadkat JD, Kelly EJ, Blough D, Cobelli C, Ahmed MS, Snodgrass WR, Carr DB, Easterling TR, Vicini P. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009, 85:607-614.
22. Yerby MS, Friel PN, McCormick K, Koerner M, Van Allen M, Leavitt AM, Sells CJ, Yerby JA. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res. 1990, 5:223-228.
23. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997, 18:404-433.
24. Kahric-Janicic N, Soldin SJ, Soldin OP, West T, Gu J, Jonklaas J. Tandem mass spectrometry improves the accuracy of free thyroxine measurements during pregnancy. Thyroid. 2007, 17:303-311.
25. Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med. 1990, 323:91-96.
26. Soldin OP, Hilakivi-Clarke L, Weiderpass E, Soldin SJ. Trimester-specific reference intervals for thyroxine and triiodothyronine in pregnancy in iodine-suffi cient women using isotope dilution tandem mass spectrometry and immunoassays. Clin Chim Acta. 2004, 349:181-189.
27. Andersson T, Flockhart DA, Goldstein DB, Huang SM, Droetz DL, Milos PM, Ratain MJ, Thummel K. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005, 78:559-581.
28. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997, 62:400-407.
29. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004, 369:23-37.
30. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009, 85:31-35.
31. Mental Health Problems of Addicted Mothers Linked to Infant Care and Development. National Pregnancy and Health Survey: National Institute on Drug Abuse. US Department of Health and Human Services 1997, 12(1). NIDA Notes
32. Ostrea EM, Brady M, Gause S, Raymundo AL, Stevens M. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics. 1992, 89:107-113.
33. Chasnoff IJ, Landress HJ, Barrett ME. The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Engl J Med. 1990, 322:1202-1206.
34. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol. 1996, 6:243-251.
35. at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. Obstet Gynecol. 2008, 112:1449-1460. ACOG Committee Opinion No. 422
36. Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction. 1993, 88:315-335.
37. Hubbard RL, French MT. New perspectives on the benefi t-cost and cost-effectiveness of drug abuse treatment. NIDA Res Monogr. 1991, 113:94-113.
38. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008, 96:69-78.
39. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009, 114:703-713.
40. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008, 69:652-658.
41. Greene MF. Teratogenicity of SSRIs-serious concern or much ado about little?. N Engl J Med. 2007, 356:2732-2733.
42. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009, 166:557-566.
43. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003, 142:402-408.
44. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fl uoxetine. N Engl J Med. 1996, 335:1010-1015.